Clinical Trials Sponsored by PhinC Development

Total 9315 results

Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)

Hematological Malignancies

United States, Belgium, Korea, Republic of, China, Germany, Israel, Netherlands, Japan, Spain, France, Poland
Ascension Healthcare Development Limited

Recruiting

A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip

Hemophilia A With Inhibitor

Russian Federation
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Recruiting

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia (ENERGY)

Warm Autoimmune Hemolytic Anemia

United States, Israel, Korea, Republic of, Spain, Czechia, France, Brazil, China, United Kingdom, Malaysia, Hungary, Japan, Poland, Germany, Ukraine, Italy, Greece, Netherlands, Egypt
Janssen Research & Development, LLC

Recruiting

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2)

Carcinoma, Non-Small-Cell Lung

Taiwan, United States, Korea, Republic of, Germany, France, China, Japan, Italy, Spain, Puerto Rico
Rural Development Trust Hospital

Recruiting

Vicente Ferrer HIV Cohort Study (VFHCS)

HIV | Tuberculosis | Cryptococcosis | Opportunistic Infections | Noncommunicable Diseases

India
Janssen Research & Development, LLC

Recruiting

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

Multidrug-Resistant Tuberculosis

Mozambique, Philippines, Russian Federation, South Africa, Uganda, Ukraine
Janssen Research & Development, LLC

Completed

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, United States, Hungary, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Amyloidosis

United States, Netherlands, Belgium, Korea, Republic of, France, Sweden, Israel, Turkey, United Kingdom, Brazil, Canada, Mexico, Australia, Germany, Japan, Spain, Denmark, Italy, China, Greece, Poland, Hungary
Janssen Research & Development, LLC

Completed

A Study of Sterile Saline Infusion in Healthy Volunteers

Healthy Volunteers

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
Janssen Research & Development, LLC

Suspended

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Germany, United States, Belgium, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

Denmark, France, Poland, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)

Hepatitis D, Chronic

France, Taiwan, Italy, Germany, Japan, Spain, Russian Federation, Turkey, United Kingdom, Australia, Sweden, United States, New Zealand, China, Brazil
Janssen Research & Development, LLC

Active, not recruiting

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older (Engage)

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

United States, Poland, Belgium, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2)

Multiple Myeloma

United States, Belgium, United Kingdom, France, Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO)

Colitis, Ulcerative

France, United States, Jordan, Taiwan, Turkey, Canada, Germany, Malaysia, New Zealand, Korea, Republic of, Hungary, Poland, Australia, Belgium, Japan, China, Israel, India, Brazil, Spain, Czechia, Argentina, Slovakia, Bulgaria, Mexico
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Taiwan, China, Korea, Republic of, Poland, Italy, Spain, Australia, Brazil, Argentina
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Neoplasms

United Kingdom, Spain, United States, Russian Federation, Poland, Sweden, Moldova, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Neoplasms | Myelodysplastic Syndromes | Non-Hodgkin Lymphoma | Solid Tumor, Adult

United States, Spain, Israel, Germany, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection (OSPREY)

Hepatitis B, Chronic

France, Belgium, Italy, United Kingdom, Poland, Spain, New Zealand, Taiwan
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (DAISY)

Arthritis, Rheumatoid

United Kingdom, United States, Germany, Argentina, Hungary, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Multiple Myeloma

Canada, United States, Israel, Czechia, Turkey, Germany, United Kingdom, Netherlands, Japan, France, Poland, Spain, Brazil
Janssen Research & Development, LLC

Active, not recruiting

A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

Canada, United States, Germany, Netherlands, Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

Plaque Psoriasis

Germany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Australia, Spain, Argentina, Japan
Janssen Research & Development, LLC

Active, not recruiting

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Carcinoma, Non-Small-Cell Lung

Taiwan, Korea, Republic of, France, Spain, United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (DHODH)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United Kingdom, France, Korea, Republic of, Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Neoplasms

Canada, Israel, Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

Canada, United States, France, Italy, United Kingdom, Germany, Belgium, Netherlands, Spain, Sweden, China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Prostatic Neoplasms

Belgium, Netherlands, Sweden, Poland, United States, France, Spain, Georgia, Moldova, Republic of, United Kingdom, Ukraine
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR)

Ulcerative Colitis

United States, Belgium, Netherlands, Japan, United Kingdom, France, Taiwan, Jordan, Turkey, Canada, Israel, Korea, Republic of, Germany, Malaysia, Hungary, Ireland, Latvia, Bulgaria, Poland, Australia, Italy, China, Spain, Russian Federation and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

Crohn Disease

Belgium, United States, Japan, Czechia, Hungary, Korea, Republic of, France, Taiwan, Germany, Malaysia, New Zealand, Poland, Canada, Turkey, Croatia, Israel, China, Denmark, Netherlands, Brazil, Italy, Spain, Jordan, Bosnia and Herzegovina and more
Janssen Research & Development, LLC

Withdrawn

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)

Relapsed/ Refractory Multiple Myeloma

United States, Poland
Janssen Research & Development, LLC

Completed

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Multiple Myeloma

Israel, Czechia, United States, Germany, Spain, United Kingdom, France, Japan, Brazil
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

Advanced or Metastatic Non-small Cell Lung Cancer

Italy, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
Janssen Research & Development, LLC

Completed

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Prostatic Neoplasms

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

HIV

Italy, Thailand, Spain, Uganda, Portugal, South Africa
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis (SUMMIT)

Plaque Psoriasis

United States, Canada, Germany, France, Spain, Poland
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant

United States, China
Janssen Research & Development, LLC

Completed

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Multiple Myeloma

Korea, Republic of, Malaysia, China, Taiwan, Hong Kong
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

Carcinoma, Non-Small-Cell Lung

United States, France, Canada, China, Israel, Belgium, United Kingdom, Italy, Argentina, Japan, Taiwan, Thailand, Korea, Republic of, Malaysia, Poland, Australia, Spain, Netherlands, Hungary, Turkey, Germany, India, Brazil, Russian Federation and more
Janssen Research & Development, LLC

Completed

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Depressive Disorder, Major

United States, France, Italy, Spain, Hungary, Belgium, Brazil, Bulgaria, Poland
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab in Participants With Active Lupus Nephritis (ORCHID-LN)

Lupus Nephritis

United States, Taiwan, Mexico, Spain, Russian Federation, Thailand, Poland, Argentina, Ukraine
Janssen Research & Development, LLC

Completed

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)

Multiple Myeloma

United States, Japan
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Alzheimer Disease

United States
Janssen Research & Development, LLC

Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Netherlands, Sweden, Denmark, France

Clinical Trials Sponsored by PhinC Development

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations